Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma
Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma
复制标题
白消安和环磷酰胺 (BU/CY2) 作为淋巴瘤患者的准备方案
DOI：
--
复制
发表时间：
1997
影响因子：
4.8
通讯作者：
Edward D. Ball
中科院分区：
文献类型：
--
作者：
M. deMagalhaes;John Lister;W. Rybka;John W. Wilson;Edward D. Ball
白消安和环磷酰胺的组合很少被用作淋巴瘤患者的预处理方案。20例复发或难治性淋巴瘤患者接受白消安（16 mg/kg）和环磷酰胺（120 mg/kg）（BU/CY）治疗，19例患者接受外周血干细胞挽救治疗，1例患者接受自体骨髓挽救治疗。有12名女性和8名男性，中位年龄为48岁（范围30-65岁）。4例患者患有霍奇金病，16例患者患有非霍奇金淋巴瘤。BU/CY时的疾病状态为：10例患者首次复发（4例患者为化疗敏感性疾病，6例患者为化疗耐药性疾病），6例患者为原发性难治性疾病，4例患者为更晚期疾病。未观察到过度给药相关毒性。无间质性肺炎病例，但发生了3例静脉闭塞性疾病。2年时，估计的总生存率和无事件生存率分别为50%和33%。我们得出结论，BU/CY似乎具有足够的抗淋巴瘤活性，没有过度毒性，需要在该患者人群中进行进一步研究。
The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma. Twenty patients with relapsed or refractory lymphoma were treated with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BU/CY) followed by peripheral blood stem cell rescue in 19 patients or autologous bone marrow in one patient. There were 12 females and eight males, with a median age of 48 years (range 30–65). Four patients had Hodgkin’s disease, and 16 patients had non-Hodgkin’s lymphoma. Disease status at the time of BU/CY was: first relapse in 10 patients (four patients with chemosensitive disease and six patients with chemoresistant disease), primary refractory disease in six patients, and more advanced disease in four patients. Excessive treatment-related toxicity was not noted. There were no cases of interstitial pneumonitis, but three cases of veno-occlusive disease occurred. At 2 years, the estimated overall survival and event-free survival are 50% and 33%. We concluded that BU/CY seems to have sufficient anti- lymphoma activity, is devoid of excessive toxicity and warrants further investigation in this patient population.